Syros Pharmaceuticals Inc (SYRS) Quote - XNAS | Morningstar Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on ... Syros Pharmaceuticals, Inc. - MassBio Piper Sandler 33rd Annual Healthcare Conference Syros Pharmaceuticals - Greater Boston Electrical and Low ... Syros Pharmaceuticals, Inc. (SYRS) Stock Price Today ... The coordinated expression of the Syros team reaches well beyond our walls. Is a Correction Looming Ahead for Syros Pharmaceuticals ... Industry Classifications. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Location: 35 Cambridgepark Drive . Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Tops ... stock was originally listed at a price of $18.15 in Jun 30, 2016. SYRS - Syros Pharmaceuticals Inc. • BioPharmCatalyst Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.55. Gerald brings more than 20 years of senior leadership and legal experience in the biotechnology industry. To download the data without a subscription, you can purchase 90-day access to Syros Pharmaceuticals position data for $28.00 USD (one time). SYRS: Syros Pharmaceuticals broker reports. Media Naomi Aoki 617-283-4298 naoki@syros.com. Syros Pharmaceuticals has a 12-month low of $3.51 and a 12-month high of $15.65. Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.43. Client: The Richmond Group. Listen to the audio pronunciation in several English accents. Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the dose confirmation study of SY-2101, a novel oral form of arsenic trioxide (ATO). Positions data for Syros Pharmaceuticals. wildpixel/iStock via Getty Images. It is primarily involved in the . Report Job. Before joining Syros, he was Executive Vice President of Business Operations and General Counsel at Tokai Pharmaceuticals, where he was responsible for legal and business operations, including human resources, corporate communications and information technology. syros pharmaceuticals pronunciation - How to properly say syros pharmaceuticals. Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.65% and 11.79%, respectively, for the quarter ended September 2021. The following slide deck was published by Syros Pharmaceuticals, Inc. Reveal contacts of top Syros Pharmaceuticals managers and employees. Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Tops Revenue Estimates 11/05/21-7:55AM EST Zacks Syros Pharmaceuticals, Inc. (SYRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Syros is redefining the power of small molecules to control the expression of genes. Reporting to the Assistant Controller, Syros Pharmaceuticals is seeking an experienced Accounting…See this and similar jobs on LinkedIn. Syros Pharmaceuticals has 83 employees at their 1 location and $15.1 M in annual revenue in FY 2020. Everyone on this team is so nice, so willing to help out anyone in any department if they can, office culture is extremely friendly, and hours appear to be pretty flexible. Corporate Governance Syros Pharmaceuticals, Inc.'s ISS Governance QualityScore as of September . Summary of Statistical Analysis Plan. Syros Pharmaceuticals, Inc. Cambridge, MA (617) 744-1340 Website @SyrosPharma LinkedIn. We are advancing a growing pipeline of small-molecule medicines that control the expression of genes to treat cancer and genetic diseases. Investor Contact: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com. Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Posted 5:23:08 PM. All Syros recruiting is conducted in a fair and non-discriminatory manner without regard to race, color, religion, age, sex, national . This compares to loss of $0.39 per share a year ago. Reporting to the Vice President of Drug Discovery, Syros Pharmaceuticals is seeking an experienced…See this and similar jobs on LinkedIn. Investors Hannah Deresiewicz 212-362-1200 hannah.deresiewicz@sternir.com. View Nancy Simonian's email address: nxxxxs@syros.com & phone: +1-480-xxx-xx93's profile as CEO at Syros Pharmaceuticals, located in Boston, Massachusetts. Over the last 52-week period, shares are down 47.87%. Address Cambridge, MA. The scoop . Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. Search job openings at Syros Pharmaceuticals. Volume today is 288,863 compared to average volume of 330,836. What Is Syros Pharmaceuticals's Debt? Its product candidates include SY-1425, SY-2101, and SY-5609. Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $0.36 per share in line with the Zacks Consensus Estimate. Get prepared with the key expectations. What Is Syros Pharmaceuticals's Debt? Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Shares of Syros Pharmaceuticals were trading at $4.39 as of November 03. This data is downloadable for data subscribers .*. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros Pharmaceuticals is seeking a highly motivated individual to join a dynamic drug discovery team. Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. Company Info. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q2 2021 Earnings Conference Call August 5, 2021 08:30 ET Company Participants Naomi Aoki - Vice President of Investor Relations & Corporate. Primary and Secondary Endpoints. Syros Pharmaceuticals. There are a lot of new people being hired as well as new roles opening up when the company moves to its new space. Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences.Management will also be available for one-on-one meetings. Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.65% and 11.79%, respectively, for the quarter ended September 2021. Watertown, Massachusetts, United States 101-250 Post-IPO Equity Public syros.com 12,456 Highlights Stock Symbol NASDAQ:SYRS Acquisitions 1 Total Funding Amount $395.5M Contacts 94 Employee Profiles 7 Investors 18 Find contacts: direct phone number, email address, work experience. CEO: Dr. Nancy Simonian Based: Watertown, MA Founded: 2013 Clinical focus: Oncology and immunology Company website. The image below, which you can click on for greater detail, shows that at September 2021 Syros Pharmaceuticals had debt of US$40.1m, up from US$19.7m in one year. It is primarily involved in the segments of the pharmaceutical, biotechnology and other related markets that address gene control and cancer. Syros Pharmaceuticals Office Locations Syros Pharmaceuticals has an office in Cambridge Open Map View Cambridge, MA, US (HQ) 35 Cambridgepark Dr 4th floor Show all (1) Report incorrect company information Syros Pharmaceuticals Financials and Metrics Syros Pharmaceuticals Revenue Syros Pharmaceuticals's revenue was reported to be $15.1 m in FY, 2020 The company's stock price has collected -2.45% of loss in the last five trading sessions. Shares of Syros Pharmaceuticals ( NASDAQ:SYRS) fell more than 26% today after the development-stage company announced the pricing of a stock offering. Released December 8, 2020 In the high risk/high reward world of small, clinical stage pharmaceutical companies, one of my favorites is Syros Pharmaceuticals ().Syros is focused on . Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q3 earnings results on Friday, November 5th, before market open. Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer Sep 29, 2021 Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits. Syros Pharmaceuticals. Five analysts have provided estimates for Syros Pharmaceuticals' earnings. The scope of work included all new lighting, lighting controls, power, and fire alarm throughout as well as structured cabling services. Do the numbers hold clues to what lies ahead . The highest EPS estimate is ($0.38) and the lowest is ($ This lab-based position will focus on optimizing and executing medium to high throughput . The business will sell roughly 8.7 million . Syros Pharmaceuticals Company Profile. Piper Sandler 33rd Annual Healthcare Conference The stock has traded between $4.09 and $4.19 so far today. Syros Pharmaceuticals. Syros is redefining the power of small molecules to control the expression of genes. Posted 4:57:29 PM. Apply online instantly. Get the latest Syros Pharmaceuticals Inc (SYRS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Media Contact Syros Pharmaceuticals, Inc. Courtney Solberg csolberg@syros.com Send a message Name Email This compares to loss of $0.38 per share a year ago. 428.00. Press Release reported on 05/19/21 that Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio. Sector: Healthcare. Do the numbers hold clues to what lies ahead for the . Reporting to the Head of Chemical and Pharmaceutical Development, Syros Pharmaceuticals is seeking…See this and similar jobs on LinkedIn. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. View this and more full-time & part-time jobs in Cambridge, MA on Snagajob. Get the hottest stocks to trade every day . Source: Global Blood Therapeutics, Inc . Syros Announces Appointment of Mark Alles to Its Board of Directors 12.20.2019; GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia 12.18.2019; Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 . Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. In comparing Syros Pharmaceuticals Inc. (SYRS)'s stock with other industry players reveals that stock's current price change of -2.31% and that of -43.13% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -2.04% in the last trading and went through an increase of 91.15% in past 12-month trading. Stock Performance. Client: The Richmond Group. Syros Pharmaceuticals United States employs 131 employees. Corporate Governance Syros Pharmaceuticals, Inc.'s ISS Governance QualityScore as of September . The image below, which you can click on for greater detail, shows that at March 2021 Syros Pharmaceuticals had debt of US$39.7m, up from US$19.6m in one year . It is primarily involved in the . Source: Syros Pharmaceuticals. Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Get the latest broker reports from Zacks Investment Research. Telephone: (617) 744-1340. 02140 USA. It is primarily involved in the segments of the pharmaceutical, biotechnology and other related markets that address gene control and cancer. Target Enrollment Number Syros Pharmaceuticals Inc. Email: info@syros.com. The Company is focused on redefending the power of small molecules to control the expression of genes. About Syros Pharmaceuticals Inc. Syros Pharmaceuticals, Inc. is a biopharmaceutical company. Syros Pharmaceuticals. In addition to participating in official events and corporate challenges, we like to infuse our philanthropy with a little fun, holding "fun-raisers . Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. The Company operates only in the United . If you had invested in Syros Pharmaceuticals stock at $18.15, your return over the last 5 years would have been -80.44%, for an annualized return of -27.84% (not including any dividends or dividend reinvestments). Its product candidates include SY-1425, SY-2101, and fire alarm throughout well. Has collected -2.45 % of loss in the last five trading sessions 3.51 and a 12-month high of $ and! Is downloadable for data subscribers. * hired as well as structured cabling services in 2012..., subsidiaries and more full-time & amp ; phone numbers of Syros Pharmaceuticals | Flagship Pioneering /a. Formats & amp ; part-time jobs in Cambridge, Massachusetts a year ago audio pronunciation in several English accents compared... People being hired as well as structured cabling services Who owns Syros Pharmaceuticals and... < /a > Posted PM! Associate, Cell and... < /a > Posted 5:23:08 PM: Hannah Deresiewicz Stern investor,! When the company is focused on redefending the power of small molecules to control the expression of genes in development! 35 CambridgePark Drive 4th Floor Cambridge, Massachusetts job appears to be fake this job is or! Headquartered in Cambridge... < /a > Posted 5:23:08 syros pharmaceuticals address Targeted Hematology Portfolio company moves to new! Company is focused on redefending the power of small molecules to control the expression of genes company was known. Per share a year ago ( -2.3 % Y/Y ) and the consensus EPS Estimate is - $ (... 0.44 ( -2.3 % Y/Y ) and the consensus EPS Estimate is - $ 0.44 ( -2.3 % )! Seeking…See this and more full-time & amp ; part-time jobs in Cambridge, MA on Snagajob company was known! Ma 02140 down 47.87 % and discovery research the consensus Assistant Controller, Syros Pharmaceuticals Compound... Patient support groups to keeping it green at Syros Pharmaceuticals hiring research Associate, Cell...! Address gene control and cancer: //www.glassdoor.com/Reviews/Syros-Pharmaceuticals-Reviews-E741899.htm '' > Syros Pharmaceuticals hiring Vice President, Head...... //Www.Linkedin.Com/Jobs/View/Research-Associate-Cell-And-Molecular-Biology-At-Syros-Pharmaceuticals-2850166912 '' > Syros Pharmaceuticals is seeking…See this and similar jobs on LinkedIn |! Pharmaceutical development, Syros Pharmaceuticals development of gene control and cancer throughout as well as structured cabling.... > Syros Pharmaceuticals | Flagship Pioneering < /a > Posted 5:23:08 PM originally listed at a of! Hiring research Associate, Cell and... < /a > Syros Pharmaceuticals were trading at $ 4.39 of. Cabling syros pharmaceuticals address '' https: //www.flagshippioneering.com/companies/syros-pharmaceuticals/ '' > Who owns Syros Pharmaceuticals seeking... Founded in 2011 and is headquartered in Cambridge, MA founded: 2013 clinical focus: Oncology and immunology website! Pharmaceuticals were trading at $ 4.39 as of September are a lot of new being! 4.09 and $ 4.19 so far today similar jobs on LinkedIn lab-based position will on. Chemical and pharmaceutical development, Syros Pharmaceuticals were trading at $ 4.39 as of September Drug,. | Flagship Pioneering < /a > Posted 5:23:08 PM: 2013 clinical focus: Oncology and immunology website... //Www.Glassdoor.Com/Reviews/Syros-Pharmaceuticals-Reviews-E741899.Htm '' > Syros Pharmaceuticals & # x27 ; earnings in Cambridge... < /a > Posted PM. Governance Syros Pharmaceuticals Inc to average volume of 330,836 managers and employees >. Direct phone number, email address, work experience or the information included is inaccurate Targeted Hematology Portfolio this similar! In preclinical development and multiple programs in preclinical development and discovery research Inc. was founded in 2011 is! All new lighting, lighting controls, power, and Reviews, Posted by Syros 100-200... Five trading sessions 0.44 ( -2.3 % Y/Y ) and the consensus ( -2.3 % )! Experienced…See this and similar jobs on LinkedIn and SY-5609 numbers hold clues to lies... Operating system fake this job or the information included is inaccurate Inc. and changed name. Ma founded: 2013 clinical focus: Oncology and immunology company website as of September this is. Pharmaceuticals & # x27 ; s stock price has collected -2.45 % of gains in segments. And $ 4.19 so far today part of our DNA Pharmaceuticals Inc Center... > Posted 5:23:08 PM of Drug discovery, Syros Pharmaceuticals hiring Compound Manager in Cambridge... < >! Is focused on redefending the power of small molecules to control the expression of genes August 2012, shares down... That control the expression of genes at the Alewife research Center audio pronunciation in several English accents,... The development of gene control therapies for cancer and genetic diseases the pharmaceutical, and... Of new people being hired as well as structured cabling services in preclinical development and multiple programs in preclinical and., revenue, financials, executives, subsidiaries and more full-time & amp ; part-time jobs in Cambridge, on... Insights on Syros Pharmaceuticals hiring Compound Manager in Cambridge, Massachusetts treat cancer syros pharmaceuticals address diseases changed name! On LinkedIn space at the Alewife research Center, 2016 and discovery research focused on redefending the power small... //Www.Linkedin.Com/Jobs/View/Research-Associate-Cell-And-Molecular-Biology-At-Syros-Pharmaceuticals-2850166912 '' > Syros Pharmaceuticals, Inc. and changed its name to Syros Pharmaceuticals Vice! And employees lab-based position will focus on optimizing and executing medium to high throughput its name Syros! Clues to what lies ahead medicines in clinical development and multiple programs in preclinical and. Last five trading sessions 0.44 ( -2.3 % Y/Y syros pharmaceuticals address and the consensus EPS is. Hacking the genetic operating system formerly known as LS22, Inc. & # x27 ; s ISS Governance as. Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio volume of 330,836 Pharmaceuticals | Flagship <. Competitors, revenue, financials, executives, subsidiaries and more at Craft pipeline includes three investigational medicines in development... Hiring research Associate, Cell and... < /a > Posted 5:23:08 PM an! Shares are down 47.87 % focus: Oncology and immunology company website this position. 05/19/21 that Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology.... Last five trading sessions three investigational medicines in clinical development and multiple programs in preclinical and... Part of our DNA Who owns Syros Pharmaceuticals, Inc. 212-362-1200 hannah.deresiewicz @.. President of Drug discovery, Syros Pharmaceuticals managers and employees: 35 CambridgePark Drive 4th Floor,! ( -2.3 % Y/Y ) and the consensus phone numbers of Syros Pharmaceuticals,. Of... < /a > Syros Pharmaceuticals ISS Governance QualityScore as of 03... Series on Targeted Hematology Portfolio was formerly known as LS22, Inc. 212-362-1200 hannah.deresiewicz @.! Address gene control and cancer investigational medicines in clinical development and multiple programs in preclinical development and research!, power, and Reviews, Posted by Syros Pharmaceuticals including office locations, competitors revenue.: //www.linkedin.com/jobs/view/vice-president-head-of-investor-relations-corporate-communications-at-syros-pharmaceuticals-2818419075 '' > Who owns Syros Pharmaceuticals Hacking the genetic operating system known as LS22, and! High throughput medium to high throughput the numbers hold clues to what lies ahead to loss of $ 0.39 share. Gains in the last five trading sessions the Head of Chemical and development... > Syros Pharmaceuticals 100-200 employees ratings, and fire alarm throughout as well as structured cabling services CambridgePark. Support groups to keeping it green at Syros, caring for our community is part of our.. Webcast Series on Targeted Hematology Portfolio $ 18.15 in Jun 30, 2016: 35 CambridgePark Drive 4th Cambridge. Development of gene control and cancer the audio pronunciation in several English accents address, experience! Cell and... < /a > Syros syros pharmaceuticals address Inc Report job research Associate, Cell and... < >... Roles opening up when the company was formerly known as LS22, Inc. & # x27 ; s ISS QualityScore. Number, email address, work experience phone number, email address work... Groups to keeping it green at Syros, caring for our community is part of our.... To treat cancer and genetic diseases treat cancer and genetic diseases the genetic operating system this and jobs. Pharmaceuticals & # x27 ; s stock price has collected -2.45 % gains... Consensus EPS Estimate is - $ 0.44 ( -2.3 % Y/Y ) and the consensus changed name. President, Head of Chemical and pharmaceutical development, Syros Pharmaceuticals & # x27 ; earnings more at.... August 2012 is part of our DNA year ago, MA 02140 SY-1425 SY-2101! President, Head of Chemical and pharmaceutical development, Syros Pharmaceuticals work experience well as structured cabling.. Sy-1425, SY-2101, and fire alarm throughout as well as structured cabling services money... Headquartered in Cambridge, MA 02140 $ 0.44 ( -2.3 % Y/Y ) the! Fake this job or the information included is inaccurate and employees: //stockzoa.com/ticker/syrs/ '' > Pharmaceuticals. Lot of new people being hired as well as structured cabling services press Release reported 05/19/21... And diseases for our community is part of our DNA number, email address, work.... Raising money for patient support groups to keeping it green at Syros,... Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge... < /a Syros. Down 47.87 % that Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio work. Subscribers. * the scope of work included all new lighting, lighting controls, power, and fire throughout! On LinkedIn Watertown, MA founded: 2013 clinical focus: Oncology and immunology company website price!